Gynecologic Oncology

Article	Citations
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer	104
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery	101
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)	101
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)	92
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes	80
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne	79
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)	77
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)	75
Prognostic factors of survival in women with recurrent platinum-resistant epithelial ovarian cancer (1171)	63
Predictors of long-term response in prospective phase II trial of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer (1247)	62
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 1203	61
TOGETHER Care: PatienT-tailOred GynEcologic Oncology posT discHargE caRe (290)	61
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)	58
Diversifying clinical trials: Does presentation at gynecologic oncology tumor board increase equitable access to clinical trials for Black and LatinX patients? (2205)	56
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)	55
Clinical impact of low-volume lymph node metastases in early- stage cervical cancer: A comprehensive meta-analysis (504)	55
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma (529)	54
Mitigating disparity? Recurrence rates and palliative care referrals by race and ethnicity across a large urban health system (514)	54
Impact of increased cycles of neoadjuvant chemotherapy on interval debulking surgery outcomes (541)	52
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)	50
Pattern of recurrence and survival: Comparative analysis of robotic radical hysterectomy with uterine manipulator versus without uterine manipulator and or vaginal cerclage in treatment of stage IB ce	49
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)	48
Creation of a surgical service line to treat patients with recurrent gynecologic cancer with curative intent: Complex oncologic multidisciplinary pelvic surgery (COMPS) (559)	48
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? – A geospatial analysis (2127)	47
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)	46

Prediction of ovarian cancer with deep machine-learning and alternative splicing (2167)	45
Metastatic site-specific prognosis of women with stage IVB cervical cancer (345)	45
Impact of venous thromboembolism on timing and outcomes of interval debulking surgery among patients treated with neoadjuvant chemotherapy for advanced ovarian cancer (370)	45
Ketogenic Diet Promotes Epithelial Ovarian Cancer Progression and Alters Tumor Gene Expression in-vivo (104)	43
Effect of sentinel lymph node isolated tumor cells on recurrence free survival in patients with mismatch repair proficient vs. deficient stage I/II endometrioid endometrial adenocarcinoma (173)	43
Development of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for patients with ovarian carcinoma (157)	42
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets (167)	42
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis	41
Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021,	41
Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)	41
Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC)	39
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial	38
Defining “enlarged” sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?	38
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group	38
Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations	37
Endometrial cancer survivors' perceptions of their cardiovascular disease risk (results from WF-1804CD AH-HA)	37
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer	37
RE1 transcription factor is decreased in endometrial cancer	36
Concurrent POLE hotspot mutations and mismatch repair deficiency in endometrial cancer: Defining cancer drivers	36
Uterine cancer among Asian Americans: Disparities & clinical characteristics and disease presentations	35
Peritoneal washing analysis in endometrial cancer: Does somatic mutation detection with panel sequencing build upon traditional cytologic analysis?	34
Spatial RNA sequencing supports programmed death ligand 2 (PD-L2) as a potential immunotherapy target in high-grade serous ovarian carcinoma	34
Patients with lower health literacy are less likely to be identified as eligible for hereditary cancer genetic testing by a digital risk stratification tool: An urban academic gynecologic oncology cli	34
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer	34
Themes, perspectives, and educational quality of content related to Pap smears on TikTok and YouTube	32
The implementation of an electronic symptom management system to monitor the severity of symptoms in gynecologic oncology patients initiating chemotherapy: A multicenter evaluation	32
The outcome of waiting for radiotherapy in locally advanced cervical cancer	32
COPANIRA: Phase Ib trial of copanlisib (PI3K inhibitor) and niraparib (PARP inhibitor) in recurrent ovarian and endometrial cancer	31
The Doc versus the Bot: A pilot study to assess the quality and accuracy of physician and chatbot responses to clinical questions in gynecologic oncology	31
The use of pedometers to assess patient ambulation following gynecologic oncology surgery: A prospective observational study	31
Outcomes among patients with chronic kidney disease undergoing HIPEC for ovarian cancer	31
Outcomes of groin recurrence in vulvar cancer after primary treatment with a sentinel lymph node procedure	31
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma	30
Defects in mismatch repair promote disease character likeness amongst Black and White women with endometrial cancer	30
Retrospective analysis of clinical features and fertility outcomes with fertility-sparing treatment of placental site trophoblastic tumor	30
Oncologic outcomes and adverse events with immunotherapy treatment among frail patients with gynecologic cancers	30
Fuzuloparib as maintenance therapy among patients with advanced ovarian cancer after a response to first-line platinum-based chemotherapy: Results from a randomized, placebo-controlled, phase III tria	30
Accuracy of patient-reported gynecologic cancer diagnoses and procedures at a large academic medical center	30
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903	29
Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial	29
Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program	29
Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer – An NRG/GOG study	29
Highlights from the 2022 Society of Gynecologic Oncology Annual Meeting on Women's Cancer	29
What are the CA-125 testing rates and their clinical implications among patients with advanced ovarian cancer treated in real-world community practice?	29
Liquid biopsy for advanced endometrial cancer: Prognostic value of plasma circulating DNA fraction in real-world settings (1320)	29
Underrepresentation of racial and ethnic minority groups in gynecologic oncology: An analysis of over 250 trials	29
The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo	28
Predictive value of the Leuven HRD test compared with Myriad myChoice PLUS on 468 ovarian cancer samples from the PAOLA-1/ENGOT-ov25 trial (LBA 6)	28
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study	28
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility	28

Trial in progress: A phase two trial of nirogacestat, a gamma-secretase inhibitor, in patients with recurrent ovarian granulosa cell tumors (NCT05348356) (1284)	28
Profiling the immune landscape in mucinous ovarian carcinoma	28
Editorial board	27
Management of chemotherapy hypersensitivity reactions and desensitization: An SGO clinical practice statement	27
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study	27
Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission	27
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies	27
Molecular comparison reveals distinct transcriptomic differences between uterine carcinosarcoma and papillary serous carcinoma distinguishable by DNA damage	27
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial	27
Recent global burden of cervical cancer incidence and mortality, predictors, and temporal trends	26
Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125	26
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas	26
CRABP2 – A novel biomarker for high-risk endometrial cancer	26
Perioperative outcomes after interval cytoreductive surgery and primary cytoreductive surgery for advanced epithelial ovarian cancer in Australia: A National Gynae-Oncology Registry (NGOR) study	26
A conceptual model of vulnerability to care delay among women at risk for endometrial cancer	26
Clinical characteristics and prognostic factors of endometrial stromal sarcoma and undifferentiated uterine sarcoma confirmed by central pathologic review: A multi-institutional retrospective study fr	26
Disparities in ovarian cancer treatment and overall survival according to race: An update	26
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs	25
Diagnostic accuracy of sentinel lymph node frozen section analysis in patients with early-stage cervical cancer: A systematic review and meta-analysis	25
Cervical Cancer Disparities in the American Indian/Alaska Native Population: Are Prevention Tools Being Utilized? (108)	25
Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer	25
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices	25
Editorial board	25
Recurrence and survival in endometrioid endometrial cancer - a population-based cohort study	25
Endometrial cancer recurrence after the use of an intrauterine manipulator during laparoscopic surgery: A retrospective cohort study (1216)	24
Obesity-related cancers disproportionately affect women compared to men in the United States (399)	24
Utilizing the KELIM score and the chemo-response score to predict chemosensitivity in ovarian cancer (1212)	24
Implementing guidelines for risk-stratified thromboprophylaxis among gynecologic oncology patients: A quality improvement initiative	24
Editorial board	24
Editorial board	24
Thoracic epidural analgesia in Gynecologic Oncology ERAS: A waste of time or time to consider it as a standard of care? (2162)	23
Lived experience of women diagnosed with a gynecologic cancer in the height of the COVID-19 pandemic in New York City (508)	23
Geographic disparities in the United States gynecologic oncology workforce: Cancer care inequities and the paradox of more docs (014)	23
The rising incidence of sex cord stromal ovarian tumors in the US: Who is most at risk? (442)	23
Telemedicine patient satisfaction metrics and methods of recurrence detection for gynecologic cancer patients throughout the initial year of the COVID-19 pandemic (515)	23
Clinical outcomes patients with high tumor mutational burden, high microsatellite stability, and mismatch repair deficiency in a multi-institutional endometrial cancer consortium (029)	23
Social precarity as a novel framework for addressing psychosocial needs of patients with gynecologic cancers (2227)	23
Sentinel lymph node biopsy compared with systematic lymphadenectomy in patients with uterine carcinosarcoma (536)	23
The impact of abortion restrictions on pregnant individuals with cancer in the United States: A statistical model (013)	23
Foreword	22
Molecular targets and prognosis for uterine cancer: What is the role of mutations of unknown significance? (1262)	22
Investigation of perturbation of DNMT and TET enzymes in endometrial cancer (308)	22
Missing the target: The oncology care model treatment pricing scheme is prohibitively reductive for gynecologic malignancies	22
Early detection of endometrial cancer	22
Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study	22
Health care services burden in ovarian cancer patients receiving PARP inhibitor maintenance treatment (377)	22
Postoperative management and outcomes before and after closure of a women's health specialty unit at a tertiary care facility	22
The impact of tumor size and histology on local control when utilizing high-dose-rate interstitial brachytherapy for gynecologic malignancies	22
Response to Letter to the Editor, Gilks et al.	22
Surgical universal euglycemic attainment during recovery (SUGAR) initiative: Sweet results through quality improvement (286)	22
Frequency of actionable germline mutations identified through tumor next generation sequencing in a gynecologic cancer cohort (394)	22
Response to Alexandre Andre B A da Costa et al.	22
Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants	21
Sensitivity of HER2-low uterine carcinosarcoma organoids to the antibody-drug conjugate, trastuzumab deruxtecan	21
The effects of a nurse-led couples intervention on marital quality of couples with gynecological cancer: A clinical randomized controlled trial	21
Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328	21
Characteristics and factors associated with mortality among cervical cancer patients undergoing palliative care	21
Variation in cervical cancer screening test utilization and results in a United States-based program	21
Efficacy and safety of tisotumab vedotin versus investigator's choice of chemotherapy in second-line or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A global,	21
Assessing the readability of online health information regarding treatment modalities for gynecologic cancer patients	20
Examining health-related quality of life outcomes among older patients with advanced ovarian cancer treated with niraparib first-line maintenance therapy in context with efficacy and safety findings:	20
Disease progression, survival, and molecular disparities among Black and White patients with endometrioid endometrial carcinoma in real-world registries and legacy NRG oncology phase III trials	20
Progression-free and overall survival of sequential platinum, taxane, and bevacizumab followed by immunotherapy may be equivalent to concurrent chemotherapy and immunotherapy among patients with recur	20
Cancer center case volume is associated with differences in the effectiveness of neoadjuvant chemotherapy for advanced-stage epithelial ovarian cancer	20
3D organoid models for predicting drug response in platinum-sensitive, high-grade serous ovarian cancer	20
Frailty does not completely explain racial disparities in postoperative outcomes after ovarian cancer debulking	20
Gamma secretase inhibitors, in combination with cytotoxic agents, decrease migration and invasion of uterine leiomyosarcoma	20
Patterns of recurrence and outcomes in vulvar extramammary Paget's disease	20
Exploring the mechanisms of resistance to trastuzumab-deruxtecan in endometrial cancer cells	19
Comparison of Enhanced Recovery After Surgery (ERAS) metrics by race among gynecologic oncology patients: Ensuring equitable outcomes	19
Cognitive outcomes after premenopausal risk-reducing Salpingo-oophorectomy: The role of hormone therapy	19
Financial toxicity among gynecologic oncology surgical patients	19
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer	19
Pathologic response to neoadjuvant chemotherapy in ovarian cancer and its association with outcome: A surrogate marker of survival	19
Overall survival in NRG258, a randomized phase III trial of chemo-radiation vs. chemotherapy alone for locally advanced endometrial carcinoma (LBA 5)	19
Feasibility of laparoscopic visceral-peritoneal debulking among patients with stage III–IV ovarian cancer: The ULTRA-LAP Pilot Trial	19
High-dose (60 Gy) intensity-modulated radiotherapy with concurrent weekly cisplatin followed by intracavitary radiation in locally advanced cervical cancer: A phase II prospective clinical trial	19
Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021	19
Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists	19
Cost-effectiveness of hyperthermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III-IV ovarian cancer from a randomized controlled phase III trial in Korea (KOV-HIPE	18

Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic	18
Modifiable pre-treatment factors are associated with quality of life in women with gynaecological cancers at diagnosis and one year later: Results from the HORIZONS UK national cohort study	18
Surgical skill and oncological outcome of laparoscopic radical hysterectomy: JGOG1081s-A1, an ancillary analysis of the Japanese Gynecologic Oncology Group Study JGOG1081	18
Does para-aortic lymphadenectomy improve survival in pathologically diagnosed early-stage grade 3 endometrioid and non-endometrioid endometrial cancers? A retrospective cohort study in Korea and Taiwa	18
Efficacy and safety of cadonilimab, an anti-PD-1/CTLA4 bi-specific antibody, in previously treated recurrent or metastatic (R/M) cervical cancer: a multicenter, open-label, single-arm, phase II trial	18
System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review	18
Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer	18
SOLAR: Phase Ib Dose Expansion of Selumetinib (MEK Inhibitor) and OLAparib (PARP Inhibitor) Combination in Solid Tumors with RAS Pathway Alterations and in PARP Inhibitor-Resistant Ovarian Cancer (LBA	18
Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/	18
Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia rece	18
Calendar-period trends in cervical precancer and cancer diagnoses since the introduction of human papillomavirus and cytology co-testing into routine cervical cancer screening at Kaiser Permanente Nor	18
TERT promoter mutations and gene amplification in endometrial cancer	18
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer	18
Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis	17
Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center	17
From FIGO-2009 to FIGO-2018 in women with early-stage cervical cancer; Does the revised staging reflect risk groups?	17
Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer	17
Molecular diversity in uterine carcinosarcoma: Beyond TP53	17
Cervical adenocarcinoma risk stratification using histotype and invasion pattern: a multicenter retrospective study by the KAMOGAWA Study Group	17
ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2, ≤50 % invasive endometrial cancer: Candidates for adjuvant therapy	17
Safety and feasibility of same day discharge for robotic hysterectomy and staging for endometrial cancer	17
The amount of preoperative endometrial tissue surface in relation to final endometrial cancer classification	17
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning	17
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression	17
Similar distribution of pelvic sentinel lymph nodes and nodal metastases in cervical and endometrial cancer. A prospective study based on lymphatic anatomy	16
Beyond Sedlis—A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis	16
Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy	16
Ovarian cancer patients demonstrating durable clinical benefit from neoadjuvant chemo-immunotherapy are associated with significant reductions in tumor-infiltrating CCR8+ regulatory T-cells	16
Screening for endometrial disease: Analyzing risk factors for abnormal endometrial pathology in a high-risk population	16
The CXCLs-CXCR2 axis modulates the cross-communication between tumor-associated neutrophils and tumor cells in cervical cancer	16
Phase I study of autologous T cells bearing fully-humanized chimeric antigen receptors targeting mesothelin in mesothelin- expressing cancers (314)	16
Whole exome sequencing provides loss of heterozygosity (LoH) data comparable to that of whole genome sequencing (171)	16
Cervical adenocarcinoma: Factors and outcomes in early-stage patients	16
Incidence and risk factors of venous and arterial thromboembolic events among patients with ovarian cancer- data from a large Canadian database	16
Factors influencing gynecologic risk reduction surgeries for BRCA1 or BRCA2 germline mutation carriers	16
Implementation of automated social determinants of health screening in gynecologic oncology: A pilot study	16
Pre-clinical investigation of a novel investigational new drug, SHetA2, for the treatment of vulvar cancer	16
Utility of germline multi-gene panel testing in patients with endometrial cancer	16
Molecular portraits of clear cell ovarian and endometrial carcinoma with comparison to clear cell renal cell carcinoma	16
Practice patterns and clinical outcomes in women with gynecologic malignancies who refuse blood products	16
Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial	16
Impact of COVID-19 on missed diagnoses of uterine cancer: Who is most affected?	16
Characteristics of mismatch repair deficient endometrial cancer in a diverse cohort	16
Editorial Board	16
Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist	16
Phase II basket study of disitamab vedotin among patients with previously-treated, locally advanced unresectable or metastatic solid tumors that express HER2: Ovarian and endometrial cancer cohorts (D	15
Microenvironment cell populations are associated with clinical outcomes in high-grade serous ovarian cancer	15
Medical decision making from the perspective of the gynecologic oncology patient	15
A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peri	15
Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021	15
Gynecologic oncology patients with severe mental illness diagnosis are more likely to experience adverse outcomes during hospitalizations for cancer-directed treatment	15
Immunotherapy: Is it all about timing?	15
Intraperitoneal therapy with engineered Newcastle disease virus encoding interleukin-12 in combination with PD-1 blockade for ovarian cancer	15
Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial cancer survivors	15
Research funding disparity in uterine cancer: An analysis of funding and race in relation to the burden of disease	15
Intra-peritoneal CAR-T cell therapy shows promising results in a murine model of epithelial ovarian cancer (313)	15
p53 functional status is associated with survival among high-grade serous ovarian cancer patients with copy number signature one	15
Evaluation of the somatic and immunologic landscapes of primary and metastatic cervical cancer to better inform future clinical trial development	15
Trends in survival of epithelial ovarian/tubal cancer by histology and socioeconomic status in Denmark 1996–2017	15
Interim post-progression data and updated survival in patients with newly diagnosed advanced ovarian cancer in ATHENA-MONO	15
Highly selective activator of Jun N-terminal kinase (JNK) for treatment of endometrioid ovarian carcinoma (1272)	14
Editorial Board	14
Impact of dose modifications due to treatment-emergent adverse events (TEAEs) on the efficacy of niraparib maintenance treatment with an individualized starting dose in patients (Pts) with newly diagn	14
P17 Evaluating a care delivery model for universal genetic testing among women with ovarian cancer	14
Disparities in the surgical treatment of loco-regional endometrial carcinoma (2120)	14
How do we decide?: Provider opioid prescribing practices (2213)	14
Identifying the molecular landscape of high risk uterine cancers: What mutations are most targetable? (1306)	14
HPV vaccination in women living with HIV in the United States (133)	14
A nomogram to predict progression-free survival benefit with maintenance olaparib and bevacizumab following response to first line chemotherapy in advanced ovarian cancer (305)	14
Clinical calculator to predict loss of independence after surgery for endometrial cancer (1190)	14
Higher US COVID-19 hospitalizations are associated with compromised endometrial cancer care; 20% fewer patients were treated surgically during the first year of the pandemic (437)	14
Isolated vaginal recurrence in women with stage I endometrial cancer	14
Open-label, phase 2, randomized controlled multicenter study comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in participants with homologous recombination defi	14
Novel serum target for early detection of ovarian cancer (2303)	14
RF5 Folate receptor alpha protein expression in ovarian serous cystadenocarcinoma tumors of The Cancer Genome Atlas: Exploration beyond single-agent therapy	14
Gestational trophoblastic neoplasia (GTN): Does centralization of care impact clinical management? (2206)	14
The evaluation of study oversight in phase 3 gynecologic cancer trials on targeted therapies over the last ten years (2229)	14
Impact of prognostic nutritional index as a predictor of immunotherapy response in patients with gynecologic cancers: Development of a clinical calculator (106)	14
The implications of the loss of abortion services from the perspective of the gynecologic cancer care team	14
Investigating exosomes in the hen model of ovarian cancer: An opportunity for early detection (2268)	14
A randomized phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer (005)	14
Building knowledge using a novel web-based intervention to promote HPV vaccination in a diverse, low-income population: Can technology standardize the message? (2171)	14
Genomic profiling and PD-L1 expression of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CIBI308ALTER-C201 trial (035)	14
Validation of a self-administered social needs assessment tool (SNAT) for the identification of actionable social needs of gynecologic oncology patients in a safety net hospital (2181)	14
Harnessing EHR for goals of care: A randomized evaluation of electronic health record alerts for patients with gynecologic malignancies at risk for death in 6 months (165)	14
Cervical cancer screening practices: Rates of underscreening, overscreening, and guideline-adherent screening in a national cohort (379)	14
My individualized risk reduction for ovarian cancer (MIRROR): Development of a patient decision aid for risk-reducing surgery in hereditary risk for ovarian cancer (158)	14
STAT3 is a potential therapeutic target in cervical cancer (257)	14
The genomic profile of high-grade serous ovarian cancer and its association with platinum resistance (2259)	14
Variation in telemedicine usage in gynecologic cancer: Are we widening or narrowing disparities?	13
Functional and psychosocial quality of life in gynecologic Cancer survivors with and without lymphedema symptoms	13
Prognostic significance of positive peritoneal cytology in endometrial carcinoma based on ESGO/ESTRO/ESP risk classification: A multicenter retrospective study	13
What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO	13
Virtual versus reality: Assessing the accuracy of a digital cancer risk assessment tool in a gynecologic oncology clinic	13
Local treatment improves survival in patients with stage IVB cervical cancer	13